Showing results 3 to 9 of 9
< previous
Title | Author(s) | Issue Date | |
---|---|---|---|
2018 | |||
2019 | |||
RETRACTION: Improved Bone Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate Over 2 Years in Patients With Chronic HBV Infection Journal:Clinical Gastroenterology and Hepatology | 2018 | ||
Review: switching patients with chronic hepatitis B to tenofovir alafenamide—a review of current data Journal:Alimentary Pharmacology & Therapeutics | 2022 | ||
Safety and efficacy at 1 year after switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in chronic HBV patients with risk factors for TDF use Proceeding/Conference:Journal of Hepatology | 2018 | ||
Tenofovir alafenamide (TAF) compared with Tenofovir Dispoproxil Fumarate (TDF) in patients with chronic HBV: week 96 efficacy and safety results in Chinese patients enrolled in 2 overseas phase 3 studies Proceeding/Conference:Chinese Infectious Disease and Hepatology Conference | 2017 | ||
2018 |